Sana Biotechnology Inc (SANA)
3.26
-0.48
(-12.83%)
USD |
NASDAQ |
Nov 05, 14:48
Sana Biotechnology Enterprise Value: 580.38M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 580.38M |
| November 01, 2024 | 562.58M |
| October 31, 2024 | 526.99M |
| October 30, 2024 | 562.58M |
| October 29, 2024 | 589.28M |
| October 28, 2024 | 620.42M |
| October 25, 2024 | 584.83M |
| October 24, 2024 | 595.95M |
| October 23, 2024 | 591.50M |
| October 22, 2024 | 615.97M |
| October 21, 2024 | 622.65M |
| October 18, 2024 | 689.39M |
| October 17, 2024 | 651.57M |
| October 16, 2024 | 689.39M |
| October 15, 2024 | 669.37M |
| October 14, 2024 | 640.45M |
| October 11, 2024 | 636.00M |
| October 10, 2024 | 600.40M |
| October 09, 2024 | 636.00M |
| October 08, 2024 | 656.02M |
| October 07, 2024 | 684.94M |
| October 04, 2024 | 689.39M |
| October 03, 2024 | 693.84M |
| October 02, 2024 | 718.31M |
| October 01, 2024 | 691.61M |
| Date | Value |
|---|---|
| September 30, 2024 | 673.82M |
| September 27, 2024 | 700.51M |
| September 26, 2024 | 698.29M |
| September 25, 2024 | 584.83M |
| September 24, 2024 | 658.24M |
| September 23, 2024 | 658.24M |
| September 20, 2024 | 693.84M |
| September 19, 2024 | 776.15M |
| September 18, 2024 | 702.74M |
| September 17, 2024 | 704.96M |
| September 16, 2024 | 718.31M |
| September 13, 2024 | 742.78M |
| September 12, 2024 | 756.13M |
| September 11, 2024 | 858.46M |
| September 10, 2024 | 860.69M |
| September 09, 2024 | 867.36M |
| September 06, 2024 | 869.59M |
| September 05, 2024 | 951.90M |
| September 04, 2024 | 971.92M |
| September 03, 2024 | 994.17M |
| August 30, 2024 | 1.094B |
| August 29, 2024 | 1.108B |
| August 28, 2024 | 1.050B |
| August 27, 2024 | 1.034B |
| August 26, 2024 | 1.048B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
122.67M
Minimum
Dec 27 2022
7.771B
Maximum
Feb 10 2021
1.475B
Average
878.99M
Median
Jul 17 2023
Enterprise Value Benchmarks
| Foghorn Therapeutics Inc | 170.73M |
| Omega Therapeutics Inc | 29.25M |
| Moderna Inc | 12.09B |
| Summit Therapeutics Inc | 14.26B |
| Apellis Pharmaceuticals Inc | 3.570B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -50.29M |
| Total Expenses (Quarterly) | 49.37M |
| EPS Diluted (Quarterly) | -0.21 |
| Earnings Yield | -35.28% |